223 related articles for article (PubMed ID: 7626494)
1. Progesterone receptor and the mechanism of action of progesterone antagonists.
Edwards DP; Altmann M; DeMarzo A; Zhang Y; Weigel NL; Beck CA
J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):449-58. PubMed ID: 7626494
[TBL] [Abstract][Full Text] [Related]
2. The antagonists RU486 and ZK98299 stimulate progesterone receptor binding to deoxyribonucleic acid in vitro and in vivo, but have distinct effects on receptor conformation.
Gass EK; Leonhardt SA; Nordeen SK; Edwards DP
Endocrinology; 1998 Apr; 139(4):1905-19. PubMed ID: 9528977
[TBL] [Abstract][Full Text] [Related]
3. Agonist and antagonists induce homodimerization and mixed ligand heterodimerization of human progesterone receptors in vivo by a mammalian two-hybrid assay.
Leonhardt SA; Altmann M; Edwards DP
Mol Endocrinol; 1998 Dec; 12(12):1914-30. PubMed ID: 9849965
[TBL] [Abstract][Full Text] [Related]
4. The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways.
Beck CA; Weigel NL; Moyer ML; Nordeen SK; Edwards DP
Proc Natl Acad Sci U S A; 1993 May; 90(10):4441-5. PubMed ID: 8389450
[TBL] [Abstract][Full Text] [Related]
5. Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP.
Sartorius CA; Tung L; Takimoto GS; Horwitz KB
J Biol Chem; 1993 May; 268(13):9262-6. PubMed ID: 8387487
[TBL] [Abstract][Full Text] [Related]
6. Characterization of ligand binding, DNA binding and phosphorylation of progesterone receptor by two novel progesterone receptor antagonist ligands.
Hurd C; Underwood B; Herman M; Iwasaki K; Kloosterboer HJ; Dinda S; Moudgil VK
Mol Cell Biochem; 1997 Oct; 175(1-2):205-12. PubMed ID: 9350053
[TBL] [Abstract][Full Text] [Related]
7. Two types of anti-progestins have distinct effects on site-specific phosphorylation of human progesterone receptor.
Beck CA; Zhang Y; Weigel NL; Edwards DP
J Biol Chem; 1996 Jan; 271(2):1209-17. PubMed ID: 8557652
[TBL] [Abstract][Full Text] [Related]
8. Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells.
Klein-Hitpass L; Cato AC; Henderson D; Ryffel GU
Nucleic Acids Res; 1991 Mar; 19(6):1227-34. PubMed ID: 2030942
[TBL] [Abstract][Full Text] [Related]
9. Effects of the steroid antagonist RU486 on dimerization of the human progesterone receptor.
DeMarzo AM; Oñate SA; Nordeen SK; Edwards DP
Biochemistry; 1992 Nov; 31(43):10491-501. PubMed ID: 1420166
[TBL] [Abstract][Full Text] [Related]
10. New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP.
Sartorius CA; Groshong SD; Miller LA; Powell RL; Tung L; Takimoto GS; Horwitz KB
Cancer Res; 1994 Jul; 54(14):3868-77. PubMed ID: 8033109
[TBL] [Abstract][Full Text] [Related]
11. ZK98299--a new antiprogesterone: biochemical characterization of steroid binding parameters in the calf uterine cytosol.
Nath R; Bhakta A; Moudgil VK
Arch Biochem Biophys; 1992 Jan; 292(1):303-10. PubMed ID: 1727646
[TBL] [Abstract][Full Text] [Related]
12. Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors.
Tung L; Mohamed MK; Hoeffler JP; Takimoto GS; Horwitz KB
Mol Endocrinol; 1993 Oct; 7(10):1256-65. PubMed ID: 8123133
[TBL] [Abstract][Full Text] [Related]
13. Novel mechanisms of progesterone antagonists and progesterone receptor.
Edwards DP; Leonhardt SA; Gass-Handel E
J Soc Gynecol Investig; 2000; 7(1 Suppl):S22-4. PubMed ID: 10732325
[TBL] [Abstract][Full Text] [Related]
14. An amino-terminal truncated progesterone receptor isoform, PRc, enhances progestin-induced transcriptional activity.
Wei LL; Hawkins P; Baker C; Norris B; Sheridan PL; Quinn PG
Mol Endocrinol; 1996 Nov; 10(11):1379-87. PubMed ID: 8923464
[TBL] [Abstract][Full Text] [Related]
15. The antiprogestins RU486 and ZK98299 affect follicle-stimulating hormone secretion differentially on estrus, but not on proestrus.
Ringstrom SJ; Szabo M; Kilen SM; Saberi S; Knox KL; Schwartz NB
Endocrinology; 1997 Jun; 138(6):2286-90. PubMed ID: 9165013
[TBL] [Abstract][Full Text] [Related]
16. Agonist and antagonist-induced qualitative and quantitative alterations of progesterone receptor from breast cancer cells.
Hurd C; Nag K; Khattree N; Alban P; Dinda S; Moudgil VK
Mol Cell Biochem; 1999 Sep; 199(1-2):49-56. PubMed ID: 10544951
[TBL] [Abstract][Full Text] [Related]
17. The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor.
Wagner BL; Norris JD; Knotts TA; Weigel NL; McDonnell DP
Mol Cell Biol; 1998 Mar; 18(3):1369-78. PubMed ID: 9488452
[TBL] [Abstract][Full Text] [Related]
18. ZK98299, a novel antiprogesterone that does not interact with chicken oviduct progesterone receptor.
Moudgil VK; Nath R; Bhakta A; Nakao M
Biochim Biophys Acta; 1991 Sep; 1094(2):185-92. PubMed ID: 1892900
[TBL] [Abstract][Full Text] [Related]
19. The novel progesterone receptor antagonists RTI 3021-012 and RTI 3021-022 exhibit complex glucocorticoid receptor antagonist activities: implications for the development of dissociated antiprogestins.
Wagner BL; Pollio G; Giangrande P; Webster JC; Breslin M; Mais DE; Cook CE; Vedeckis WV; Cidlowski JA; McDonnell DP
Endocrinology; 1999 Mar; 140(3):1449-58. PubMed ID: 10067874
[TBL] [Abstract][Full Text] [Related]
20. Modulators of cellular protein phosphorylation alter the trans-activation function of human progesterone receptor and the biological activity of progesterone antagonists.
Edwards DP; Weigel NL; Nordeen SK; Beck CA
Breast Cancer Res Treat; 1993; 27(1-2):41-56. PubMed ID: 8260729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
